Views & Analysis | Perspectives on pharma industry issues

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

R&D

Sponsored

Turning recruitment potential into enrolment reality

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Articles

Publication of clinical trial data: enough of the excuses!

How much negative data goes unpublished? Ryan Woodrow set to find out and his surprising results are detailed here. I attended a MedComms Networking event last summer to listen to the thoughts of Ben Goldacre on the pharmaceutical industry. For those of you who...

Articles

Payers and personalised medicine: considerations for success

Andree Bates questions the slow uptake of personalised medicine diagniostic tests - are payers proving to be a barrier in this area? Gleevec and Herceptin (and their clinical and commercial success), were pioneering drugs in terms of...

Articles

Patent expiry & social media: a pharma story of biblical sig...

Richard Heale highlights the link between patent expiration in pharma and social media. In the beginning Pharma created its ‘block-buster’ fatted calves. Protected by aging patents they will over the next six years put US$267 billion of revenue at risk through patent expiry...

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

Sales & Marketing

Sponsored

Accelerating growth through strategic investment in healthca...

CEVA FORPATIENTS at Rockingham, UK will offer the healthcare supply chain a new, sustainably designed multi-user site.

Digital

Sponsored

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Digital

Two female silhouettes in a city office overlook the urban landscape below

How female leadership can benefit industry

Day One Strategy’s founding partners Abigail Stuart and Hannah Mann share the benefits female leadership can bring to industry.

Market Access

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Market Access

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Oncology